KC
SABSW icon

Kepos Capital’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Kepos Capital’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-199,261
Closed -$183K – 669
2021
Q3 		$183K Buy
199,261
+48,386
+32% +$34.6K 0.01% 474
2021
Q2 		$139K Buy
+150,875
New +$110K 0.01% 425

Other funds holding SABSW

SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
ICMH
Integrity Capital Management (HK) Central, Hong Kong $64K AUM
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Kepos Capital's SABSW Position: Q4 2021 in Review

Kepos Capital sold out of SAB Biotherapeutics Warrant (SABSW) in Q4 2021, closing a stake of 199,261 shares — an estimated $183K sold.

Kepos Capital first reported a position in SABSW in Q2 2021 and held it in 2 quarters. The position peaked at $183K in Q3 2021. 21 funds tracked by Wall St. Rank hold SABSW as of Q4 2021.

  • Kepos Capital reported no remaining SAB Biotherapeutics Warrant position as of Q4 2021 after selling out during the quarter.
  • Kepos Capital sold 199,261 SAB Biotherapeutics Warrant shares in Q4 2021, an estimated $183K.
  • Kepos Capital first reported a position in SAB Biotherapeutics Warrant in Q2 2021 and held it in 2 quarters.
  • Kepos Capital's SAB Biotherapeutics Warrant position peaked at $183K in Q3 2021.
  • 21 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q4 2021.

Based on Kepos Capital's 13F filing for Q4 2021, filed 14 Feb 2022.